ADC Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
ZYNLONTA is positioned for significant growth, with pivotal LOTIS-5 and LOTIS-7 trial data expected in 2024. Expansion into second-line DLBCL and indolent lymphomas could drive peak sales to $600M–$1B, supported by a strong cash position and strategic flexibility.
-
ZYNLONTA is positioned for significant growth with pivotal phase III and combination study data expected this year, targeting both complex and broadly accessible DLBCL segments. Early results show high response rates and manageable safety, with expansion into indolent lymphomas and second-line settings projected to drive revenue growth to $600 million–$1 billion.
-
Zynlonta is expanding from third line DLBCL into earlier lines and indolent lymphomas, with pivotal LOTIS-5 and LOTIS-7 trials expected to drive significant revenue growth from 2027. Strong efficacy, rapid response, and a favorable safety profile position it competitively in both complex and broadly accessible therapy segments.
Fiscal Year 2025
-
ZYNLONTA revenues grew in Q4 2025, with stable annual sales and reduced operating expenses. Strategic focus on expanding indications and strong cash position support long-term growth, with key clinical data readouts expected in 2026 and 2027.
-
Updated LOTIS-7 data show ZYNLONTA plus glofitamab achieved an 89.8% ORR and 77.6% CR rate in second-line plus DLBCL, with durable responses and a manageable safety profile. Lower CRS rates and strong efficacy in relapsed and refractory patients support further development.
-
ZYNLONTA maintains a stable 10% share in third-line DLBCL, with strong efficacy and safety. Key trials (LOTIS-5 and LOTIS-7) aim to expand indications and market size, targeting up to $800M in combined opportunities. Cash runway extends into 2028.
-
ZYNLONTA is positioned for growth in DLBCL with strong academic and community support, targeting both broadly accessible and complex therapy segments. Key trials (LOTIS-5 and LOTIS-7) are progressing, with promising efficacy and safety data, and additional opportunities in indolent lymphomas and pipeline assets.
-
Q3 2025 net product revenues were $15.8M, with operating expenses down 12.1% year-over-year. Key clinical trials (LOTIS-5, LOTIS-7) are progressing, and a $60M financing extends cash runway to 2028. ZYNLONTA's market potential is estimated at $600M–$1B in peak annual U.S. revenue.
-
ZYNLONTA is being advanced as a potential new standard in DLBCL, with strong efficacy and safety data from LOTIS-5 and LOTIS-7 trials. High response rates in indolent lymphomas and a robust cash position support multiple upcoming catalysts through 2027.
-
Q2 2025 saw modest revenue growth and strong clinical data for ZYNLONTA combinations in DLBCL, with a strategic focus on core assets and a $100 million private placement extending cash runway into 2028. Multiple data catalysts and regulatory milestones are expected through 2026.
-
LOTIS-7 phase Ib data show ZYNLONTA plus glofitamab yields a 93% ORR and 87% CR rate in relapsed/refractory LBCL, with a manageable safety profile and rapid, durable responses. The 150 mcg/kg dose is advancing to expansion, supporting regulatory and commercial potential.
-
ZYNLONTA maintains a strong position in DLBCL, with promising data from LOTIS-5 and LOTIS-7 studies and expansion into indolent lymphomas. Financial runway extends into 2026, with major growth expected from 2027 as new indications and partnerships advance.
-
Q1 2025 revenues reached $23M, with ZYNLONTA maintaining strong performance and promising LOTIS-7 data showing a 95.5% response rate. Cash runway extends into H2 2026, and key trial updates are expected at EHA and ICML.
-
Zynlonta is positioned for significant growth through expansion into earlier DLBCL lines and combinations, with strong efficacy and safety data supporting regulatory and compendia strategies. The company’s novel ADC pipeline and solid tumor programs are advancing, with key milestones expected in 2024 and a path to profitability by 2027.
-
Zynlonta maintains strong sales despite new competition, with major growth expected from new indications and guideline inclusions. High response rates in indolent lymphoma and promising combination data with glofitamab could expand market share, while early-stage ADC candidates advance toward IND with partnership opportunities.
Fiscal Year 2024
-
2024 saw stable ZYNLONTA revenues, reduced operating expenses, and a strengthened balance sheet. Key clinical milestones were achieved, with promising data from LOTIS-5, LOTIS-7, and indolent lymphoma studies, supporting significant future growth opportunities.
-
Initial LOTIS-7 phase 1-B results show ZYNLONTA plus glofitamab achieved a 94% overall response and 72% complete response rate in relapsed/refractory DLBCL, with a manageable safety profile and no high-grade CRS or ICANS. The combination is positioned for expansion into earlier lines and broader care settings.
-
Significant pipeline progress was highlighted, including strong commercial performance and expansion into earlier DLBCL lines, with key data readouts for LOTIS-5 and LOTIS-7 expected by year-end. Promising results in indolent lymphomas and a strategic shift to a next-gen exatecan ADC platform were also discussed.
-
Zynlonta continues to show strong efficacy and safety in DLBCL and indolent lymphomas, with expansion into earlier lines and combinations poised to triple its commercial potential. The pipeline leverages a differentiated exatecan platform, with multiple preclinical assets advancing toward IND-enabling stages.
-
Q3 2024 saw stable ZYNLONTA revenues and strong cash reserves, with clinical progress in DLBCL and indolent lymphomas. Solid tumor focus shifted to exatecan-based ADCs, and key data readouts are expected in December and 2025.
-
The company has streamlined its portfolio, focusing on Zynlonta and expanding into earlier DLBCL lines with promising combination trials. Indolent lymphoma studies show high response rates, and a solid tumor candidate is advancing. Cash reserves support key data readouts through 2026.
-
The discussion highlighted robust clinical progress and expansion plans for Zynlonta, with significant opportunities in earlier DLBCL lines and indolent lymphomas. The solid tumor pipeline is advancing, supported by a strong financial position and strategic focus on partnerships.
-
Q2 2024 saw commercial profitability for ZYNLONTA, with $17M in revenue and reduced operating expenses. Key clinical trials (LOTIS-5, LOTIS-7) are progressing, and a $105M financing extended the cash runway into mid-2026.
-
The company is advancing a dual hematology and solid tumor pipeline, with ZYNLONTA driving near-term growth through pivotal trials and expansion into new indications. Solid tumor assets are progressing in early-stage studies, with a focus on partnerships and a strong cash position supporting key milestones through 2026.